|
CN104224691A
|
|
Moxifloxacin hydrochloride external preparation and preparation method thereof
|
|
CN104224802A
|
|
Moxifloxacin hydrochloride ear drops and preparation method thereof
|
|
CN103992306A
|
|
Preparing and refining method of S-pantoprazole sodium
|
|
CN103992337A
|
|
Convenient method for preparing aspoxicillin sodium
|
|
CN105001166A
|
|
New impurity of erlotinib, and preparation method thereof
|
|
CN104211701A
|
|
Method for preparing moxifloxacin impurities B and D
|
|
CN104945399A
|
|
Method for preparing Moxifloxacin impurity C
|
|
CN104945398A
|
|
Method for preparing Moxifloxacin impurity E
|
|
CN103755648A
|
|
New impurity of gefitinib and preparation method thereof
|
|
CN103739558A
|
|
Method for preparing known impurities of gefitinib
|
|
CN103483314A
|
|
Method for preparing imatinib mesylate in alpha crystal form conveniently and rapidly
|
|
CN103396371A
|
|
Preparation method of erlotinib hydrochloride crystal form A
|
|
CN103396416A
|
|
Preparation method of moxifloxacin impurity F
|
|
CN103664738A
|
|
Crystalline polymorphic substance of carboxamide compound L-malate
|
|
CN102702068A
|
|
3-pyrrolo-cyclohexylidene-2-dihydroindolone derivative, and application of 3-pyrrolo-cyclohexylidene-2-dihydroindolone derivative
|
